| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 187 | 2024 | 3022 | 14.500 |
Why?
|
| Nephrectomy | 110 | 2023 | 779 | 12.690 |
Why?
|
| Carcinoma, Transitional Cell | 69 | 2023 | 962 | 11.820 |
Why?
|
| Ureteral Neoplasms | 50 | 2023 | 228 | 11.330 |
Why?
|
| Carcinoma, Renal Cell | 122 | 2024 | 2326 | 8.900 |
Why?
|
| Urologic Neoplasms | 23 | 2021 | 188 | 7.400 |
Why?
|
| Ureter | 28 | 2023 | 209 | 5.760 |
Why?
|
| Laparoscopy | 44 | 2016 | 1225 | 5.230 |
Why?
|
| Urinary Bladder Neoplasms | 45 | 2023 | 2341 | 4.450 |
Why?
|
| Robotics | 14 | 2016 | 359 | 3.090 |
Why?
|
| Lymph Node Excision | 23 | 2024 | 1959 | 2.800 |
Why?
|
| Kidney | 29 | 2023 | 2146 | 2.550 |
Why?
|
| Catheter Ablation | 17 | 2016 | 620 | 2.410 |
Why?
|
| Kidney Pelvis | 14 | 2023 | 102 | 2.260 |
Why?
|
| Nephroureterectomy | 12 | 2023 | 39 | 2.250 |
Why?
|
| Prostatectomy | 14 | 2021 | 962 | 2.210 |
Why?
|
| Mitomycin | 10 | 2023 | 208 | 2.090 |
Why?
|
| Cryosurgery | 9 | 2021 | 167 | 1.930 |
Why?
|
| von Hippel-Lindau Disease | 7 | 2018 | 115 | 1.820 |
Why?
|
| Cystectomy | 13 | 2021 | 623 | 1.790 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2019 | 469 | 1.540 |
Why?
|
| Watchful Waiting | 4 | 2018 | 289 | 1.440 |
Why?
|
| Humans | 300 | 2024 | 261506 | 1.430 |
Why?
|
| Male | 205 | 2024 | 123000 | 1.410 |
Why?
|
| Urinary Bladder | 7 | 2021 | 575 | 1.400 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2021 | 726 | 1.390 |
Why?
|
| Urothelium | 9 | 2022 | 254 | 1.360 |
Why?
|
| Ablation Techniques | 4 | 2021 | 148 | 1.320 |
Why?
|
| Ureteroscopy | 12 | 2023 | 46 | 1.270 |
Why?
|
| Aged | 142 | 2021 | 70117 | 1.270 |
Why?
|
| Middle Aged | 161 | 2023 | 86204 | 1.230 |
Why?
|
| Carcinoma in Situ | 4 | 2018 | 487 | 1.190 |
Why?
|
| Neoplasms, Second Primary | 8 | 2021 | 1350 | 1.180 |
Why?
|
| Female | 181 | 2021 | 141928 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 36 | 2023 | 10035 | 1.070 |
Why?
|
| Retrospective Studies | 95 | 2024 | 37905 | 1.070 |
Why?
|
| Neoplasm Staging | 41 | 2024 | 13658 | 1.060 |
Why?
|
| Pyrroles | 10 | 2016 | 576 | 1.010 |
Why?
|
| Carcinoma | 7 | 2021 | 2578 | 1.000 |
Why?
|
| Urinary Tract | 4 | 2023 | 82 | 0.980 |
Why?
|
| Cytoreduction Surgical Procedures | 11 | 2023 | 475 | 0.960 |
Why?
|
| Venous Thrombosis | 4 | 2022 | 384 | 0.960 |
Why?
|
| Treatment Outcome | 80 | 2021 | 32848 | 0.940 |
Why?
|
| Urologic Surgical Procedures | 10 | 2016 | 93 | 0.940 |
Why?
|
| Aged, 80 and over | 65 | 2021 | 29902 | 0.900 |
Why?
|
| Indoles | 10 | 2016 | 1009 | 0.900 |
Why?
|
| Quality of Life | 9 | 2017 | 4532 | 0.870 |
Why?
|
| Chylous Ascites | 1 | 2022 | 25 | 0.840 |
Why?
|
| Prostatic Neoplasms | 15 | 2021 | 5767 | 0.830 |
Why?
|
| Warm Ischemia | 4 | 2014 | 22 | 0.790 |
Why?
|
| Uncertainty | 2 | 2013 | 320 | 0.780 |
Why?
|
| Neoplasms, Multiple Primary | 4 | 2021 | 551 | 0.780 |
Why?
|
| Angiogenesis Inhibitors | 8 | 2018 | 1248 | 0.760 |
Why?
|
| Prospective Studies | 30 | 2024 | 12873 | 0.760 |
Why?
|
| Urology | 7 | 2016 | 128 | 0.740 |
Why?
|
| Thrombectomy | 5 | 2022 | 158 | 0.720 |
Why?
|
| Neoadjuvant Therapy | 17 | 2023 | 4975 | 0.720 |
Why?
|
| Penile Neoplasms | 3 | 2024 | 161 | 0.710 |
Why?
|
| Penis | 2 | 2013 | 123 | 0.690 |
Why?
|
| Adjuvants, Immunologic | 3 | 2022 | 657 | 0.680 |
Why?
|
| Ultrasonography | 7 | 2018 | 1863 | 0.680 |
Why?
|
| Antineoplastic Agents | 21 | 2021 | 14289 | 0.650 |
Why?
|
| Angiomyolipoma | 2 | 2020 | 31 | 0.640 |
Why?
|
| Salvage Therapy | 2 | 2018 | 2054 | 0.630 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 335 | 0.620 |
Why?
|
| Neoplasm Grading | 14 | 2021 | 1742 | 0.610 |
Why?
|
| Retroperitoneal Space | 9 | 2022 | 145 | 0.610 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 24 | 0.600 |
Why?
|
| Education, Medical, Graduate | 4 | 2017 | 671 | 0.600 |
Why?
|
| Lymphatic Metastasis | 14 | 2021 | 4844 | 0.600 |
Why?
|
| Adult | 83 | 2021 | 77950 | 0.590 |
Why?
|
| Ureteral Obstruction | 3 | 2023 | 143 | 0.590 |
Why?
|
| Cold Ischemia | 2 | 2014 | 22 | 0.590 |
Why?
|
| Inguinal Canal | 4 | 2024 | 60 | 0.570 |
Why?
|
| Videoconferencing | 2 | 2018 | 56 | 0.570 |
Why?
|
| Maintenance Chemotherapy | 1 | 2017 | 202 | 0.560 |
Why?
|
| Chemotherapy, Adjuvant | 16 | 2023 | 3890 | 0.550 |
Why?
|
| Multigene Family | 1 | 2017 | 425 | 0.540 |
Why?
|
| Endoscopy | 3 | 2018 | 479 | 0.530 |
Why?
|
| Adaptation, Psychological | 4 | 2017 | 764 | 0.520 |
Why?
|
| Adrenalectomy | 4 | 2011 | 188 | 0.490 |
Why?
|
| Survival Rate | 28 | 2021 | 12221 | 0.480 |
Why?
|
| Follow-Up Studies | 30 | 2021 | 14889 | 0.480 |
Why?
|
| Postoperative Care | 2 | 2016 | 739 | 0.480 |
Why?
|
| Neoplasm Invasiveness | 9 | 2021 | 3981 | 0.480 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 669 | 0.480 |
Why?
|
| Ischemic Preconditioning | 1 | 2013 | 20 | 0.460 |
Why?
|
| Telemedicine | 3 | 2018 | 471 | 0.460 |
Why?
|
| Feasibility Studies | 12 | 2018 | 2292 | 0.460 |
Why?
|
| Video-Assisted Surgery | 1 | 2013 | 28 | 0.450 |
Why?
|
| Disease-Free Survival | 21 | 2021 | 10001 | 0.440 |
Why?
|
| Patient Selection | 10 | 2020 | 2055 | 0.430 |
Why?
|
| Risk Factors | 32 | 2021 | 17523 | 0.430 |
Why?
|
| Vena Cava, Inferior | 3 | 2022 | 190 | 0.420 |
Why?
|
| Sulfonamides | 2 | 2018 | 1823 | 0.410 |
Why?
|
| Image-Guided Biopsy | 1 | 2014 | 327 | 0.410 |
Why?
|
| Neuroendocrine Tumors | 2 | 2016 | 634 | 0.410 |
Why?
|
| Risk Assessment | 23 | 2023 | 6869 | 0.400 |
Why?
|
| Pancreatectomy | 1 | 2016 | 652 | 0.400 |
Why?
|
| Acute Kidney Injury | 2 | 2013 | 739 | 0.390 |
Why?
|
| Robotic Surgical Procedures | 5 | 2024 | 481 | 0.390 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 799 | 0.380 |
Why?
|
| Peritoneum | 1 | 2011 | 150 | 0.380 |
Why?
|
| Cystoscopy | 2 | 2016 | 88 | 0.370 |
Why?
|
| Everolimus | 3 | 2020 | 415 | 0.370 |
Why?
|
| Laparoscopes | 1 | 2009 | 10 | 0.360 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 361 | 0.360 |
Why?
|
| Recovery of Function | 3 | 2012 | 703 | 0.360 |
Why?
|
| Cisplatin | 6 | 2023 | 2432 | 0.360 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2021 | 6207 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 21 | 2017 | 7551 | 0.350 |
Why?
|
| Proportional Hazards Models | 16 | 2021 | 4988 | 0.350 |
Why?
|
| Combined Modality Therapy | 13 | 2021 | 8865 | 0.350 |
Why?
|
| Minimally Invasive Surgical Procedures | 7 | 2016 | 500 | 0.350 |
Why?
|
| Biopsy, Needle | 4 | 2010 | 1363 | 0.350 |
Why?
|
| Kidney Diseases | 4 | 2014 | 691 | 0.340 |
Why?
|
| Ischemia | 1 | 2012 | 391 | 0.340 |
Why?
|
| Nephrostomy, Percutaneous | 3 | 2018 | 55 | 0.340 |
Why?
|
| Genetic Testing | 1 | 2017 | 1589 | 0.340 |
Why?
|
| Administration, Topical | 3 | 2018 | 257 | 0.340 |
Why?
|
| Sirolimus | 1 | 2013 | 814 | 0.330 |
Why?
|
| Prostate | 3 | 2019 | 1088 | 0.330 |
Why?
|
| Kidney Function Tests | 5 | 2015 | 192 | 0.330 |
Why?
|
| Thrombosis | 2 | 2018 | 781 | 0.330 |
Why?
|
| Program Evaluation | 1 | 2011 | 597 | 0.330 |
Why?
|
| Pyrimidines | 2 | 2018 | 3518 | 0.330 |
Why?
|
| Biomarkers, Tumor | 8 | 2021 | 10331 | 0.320 |
Why?
|
| Microsatellite Instability | 3 | 2019 | 400 | 0.320 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 48 | 0.310 |
Why?
|
| Photochemotherapy | 1 | 2008 | 96 | 0.310 |
Why?
|
| Learning | 1 | 2011 | 403 | 0.310 |
Why?
|
| Teaching | 1 | 2009 | 243 | 0.310 |
Why?
|
| BCG Vaccine | 3 | 2021 | 399 | 0.300 |
Why?
|
| Neoplasm Seeding | 2 | 2021 | 66 | 0.300 |
Why?
|
| Hernia, Ventral | 1 | 2009 | 159 | 0.300 |
Why?
|
| Adrenal Gland Neoplasms | 6 | 2018 | 489 | 0.300 |
Why?
|
| Endosonography | 1 | 2010 | 536 | 0.290 |
Why?
|
| Genomics | 2 | 2017 | 2738 | 0.290 |
Why?
|
| Diagnostic Imaging | 3 | 2010 | 1162 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 4 | 2022 | 602 | 0.290 |
Why?
|
| Prognosis | 29 | 2023 | 21713 | 0.290 |
Why?
|
| Preoperative Period | 5 | 2019 | 344 | 0.290 |
Why?
|
| Postoperative Complications | 12 | 2023 | 5542 | 0.290 |
Why?
|
| Texas | 11 | 2018 | 6311 | 0.280 |
Why?
|
| Writing | 3 | 2017 | 104 | 0.270 |
Why?
|
| Lymph Nodes | 5 | 2024 | 2967 | 0.270 |
Why?
|
| Radiography | 4 | 2013 | 1904 | 0.270 |
Why?
|
| Cohort Studies | 14 | 2020 | 9244 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2018 | 5539 | 0.250 |
Why?
|
| Forearm | 1 | 2005 | 67 | 0.250 |
Why?
|
| Patient Discharge | 2 | 2022 | 661 | 0.250 |
Why?
|
| Education, Medical, Continuing | 2 | 2009 | 251 | 0.250 |
Why?
|
| Time Factors | 19 | 2021 | 12926 | 0.250 |
Why?
|
| Sutures | 2 | 2013 | 86 | 0.250 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 1724 | 0.250 |
Why?
|
| Arteries | 1 | 2006 | 274 | 0.250 |
Why?
|
| Cell Dedifferentiation | 3 | 2020 | 96 | 0.250 |
Why?
|
| Hydrogels | 2 | 2021 | 123 | 0.240 |
Why?
|
| Nomograms | 4 | 2019 | 313 | 0.240 |
Why?
|
| Sarcoma, Synovial | 1 | 2005 | 119 | 0.240 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2017 | 155 | 0.230 |
Why?
|
| Solitary Kidney | 1 | 2023 | 1 | 0.230 |
Why?
|
| Urinary Diversion | 2 | 2010 | 69 | 0.230 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.230 |
Why?
|
| Pancreatic Neoplasms | 3 | 2016 | 5061 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2018 | 607 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2023 | 15862 | 0.230 |
Why?
|
| Cyanoacrylates | 1 | 2003 | 41 | 0.230 |
Why?
|
| Radiosurgery | 2 | 2024 | 1330 | 0.230 |
Why?
|
| Tissue Adhesives | 1 | 2003 | 51 | 0.230 |
Why?
|
| Heart Diseases | 1 | 2009 | 732 | 0.220 |
Why?
|
| Pheochromocytoma | 4 | 2008 | 281 | 0.220 |
Why?
|
| Chordoma | 1 | 2005 | 163 | 0.220 |
Why?
|
| Renal Artery | 2 | 2016 | 79 | 0.220 |
Why?
|
| Tumor Burden | 7 | 2018 | 1987 | 0.220 |
Why?
|
| Urogenital Neoplasms | 1 | 2003 | 108 | 0.220 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2002 | 31 | 0.220 |
Why?
|
| Enoxaparin | 1 | 2022 | 66 | 0.210 |
Why?
|
| Survival Analysis | 11 | 2021 | 9180 | 0.210 |
Why?
|
| Electromagnetic Phenomena | 1 | 2001 | 18 | 0.210 |
Why?
|
| Intraoperative Care | 3 | 2018 | 259 | 0.210 |
Why?
|
| Young Adult | 20 | 2021 | 21445 | 0.210 |
Why?
|
| Constriction, Pathologic | 4 | 2023 | 310 | 0.210 |
Why?
|
| Lithotripsy | 1 | 2001 | 21 | 0.210 |
Why?
|
| Decompression, Surgical | 1 | 2002 | 143 | 0.210 |
Why?
|
| Bone Neoplasms | 4 | 2020 | 2576 | 0.210 |
Why?
|
| Pelvic Neoplasms | 1 | 2023 | 189 | 0.200 |
Why?
|
| Catheterization | 2 | 2003 | 410 | 0.200 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 2864 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8873 | 0.200 |
Why?
|
| Lymphocytes | 3 | 2020 | 1234 | 0.200 |
Why?
|
| Hematoma | 1 | 2002 | 160 | 0.200 |
Why?
|
| Mutation | 3 | 2019 | 15179 | 0.200 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 3251 | 0.200 |
Why?
|
| Creatinine | 4 | 2023 | 531 | 0.200 |
Why?
|
| Biopsy | 8 | 2021 | 3443 | 0.200 |
Why?
|
| Carcinogenesis | 2 | 2018 | 1026 | 0.200 |
Why?
|
| Iatrogenic Disease | 1 | 2022 | 183 | 0.190 |
Why?
|
| Nephrons | 3 | 2023 | 48 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 259 | 0.190 |
Why?
|
| Dissection | 3 | 2018 | 156 | 0.190 |
Why?
|
| Operative Time | 3 | 2019 | 217 | 0.190 |
Why?
|
| Lymphocele | 1 | 2000 | 8 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 2291 | 0.190 |
Why?
|
| CTLA-4 Antigen | 2 | 2021 | 657 | 0.190 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2015 | 262 | 0.190 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 90 | 0.190 |
Why?
|
| Abdominal Wall | 1 | 2003 | 184 | 0.190 |
Why?
|
| Interferon-alpha | 2 | 2003 | 889 | 0.180 |
Why?
|
| Predictive Value of Tests | 5 | 2018 | 4892 | 0.180 |
Why?
|
| Kidney Calculi | 1 | 2000 | 40 | 0.180 |
Why?
|
| Vasovasostomy | 2 | 2004 | 23 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 1 | 2001 | 210 | 0.180 |
Why?
|
| Pyridones | 1 | 2022 | 348 | 0.180 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2021 | 4757 | 0.180 |
Why?
|
| Neoplasm Metastasis | 12 | 2021 | 5112 | 0.180 |
Why?
|
| Deoxycytidine | 3 | 2023 | 1353 | 0.180 |
Why?
|
| Margins of Excision | 2 | 2018 | 285 | 0.170 |
Why?
|
| Sensitivity and Specificity | 9 | 2019 | 4971 | 0.170 |
Why?
|
| Renal Veins | 3 | 2017 | 56 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 62 | 0.170 |
Why?
|
| Indazoles | 2 | 2018 | 297 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2019 | 82 | 0.170 |
Why?
|
| Radiology | 2 | 2021 | 434 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2003 | 411 | 0.170 |
Why?
|
| Drug Carriers | 1 | 2020 | 327 | 0.170 |
Why?
|
| Gene Expression Profiling | 8 | 2019 | 5159 | 0.160 |
Why?
|
| Glycemic Load | 1 | 2017 | 6 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2017 | 29 | 0.160 |
Why?
|
| Patient Satisfaction | 3 | 2017 | 915 | 0.160 |
Why?
|
| Carbohydrates | 1 | 2017 | 68 | 0.150 |
Why?
|
| Adolescent | 16 | 2018 | 31252 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 43 | 0.150 |
Why?
|
| Ileostomy | 1 | 2018 | 46 | 0.150 |
Why?
|
| Intraoperative Period | 3 | 2020 | 246 | 0.150 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2005 | 882 | 0.150 |
Why?
|
| Urinary Catheterization | 1 | 2018 | 117 | 0.150 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 33 | 0.150 |
Why?
|
| Neutrophils | 2 | 2020 | 835 | 0.150 |
Why?
|
| Ultrasonography, Interventional | 2 | 2018 | 429 | 0.150 |
Why?
|
| DNA Mismatch Repair | 1 | 2019 | 268 | 0.150 |
Why?
|
| Sequence Analysis, RNA | 2 | 2019 | 651 | 0.150 |
Why?
|
| Case-Control Studies | 9 | 2018 | 6100 | 0.150 |
Why?
|
| Receptors, Leptin | 1 | 2017 | 62 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2010 | 7222 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2023 | 716 | 0.150 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 81 | 0.150 |
Why?
|
| Clinical Competence | 4 | 2009 | 1270 | 0.150 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 172 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 3 | 2020 | 4367 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2022 | 787 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 223 | 0.140 |
Why?
|
| Expressed Emotion | 1 | 2016 | 22 | 0.140 |
Why?
|
| Mutation Rate | 1 | 2017 | 223 | 0.140 |
Why?
|
| DNA Methylation | 2 | 2017 | 2669 | 0.140 |
Why?
|
| DNA Mutational Analysis | 3 | 2019 | 2283 | 0.140 |
Why?
|
| Age Factors | 5 | 2014 | 5377 | 0.140 |
Why?
|
| Logistic Models | 7 | 2020 | 3441 | 0.140 |
Why?
|
| Niacinamide | 2 | 2016 | 421 | 0.140 |
Why?
|
| Incidence | 5 | 2021 | 5673 | 0.140 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 7548 | 0.130 |
Why?
|
| Administration, Intravesical | 4 | 2020 | 162 | 0.130 |
Why?
|
| Meat | 1 | 2015 | 87 | 0.130 |
Why?
|
| Adrenal Glands | 1 | 2015 | 122 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2022 | 851 | 0.130 |
Why?
|
| Uroplakin III | 1 | 2014 | 8 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 529 | 0.130 |
Why?
|
| Uroplakin II | 1 | 2014 | 15 | 0.130 |
Why?
|
| Pelvis | 3 | 2021 | 362 | 0.130 |
Why?
|
| Hepatomegaly | 1 | 2014 | 69 | 0.130 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 376 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 2330 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2013 | 5687 | 0.130 |
Why?
|
| CpG Islands | 1 | 2017 | 633 | 0.130 |
Why?
|
| Carcinoma, Medullary | 1 | 2016 | 248 | 0.130 |
Why?
|
| Radiography, Interventional | 4 | 2011 | 305 | 0.130 |
Why?
|
| Mutagens | 1 | 2015 | 187 | 0.130 |
Why?
|
| Aneurysm, False | 1 | 2016 | 153 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 1053 | 0.120 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 580 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 769 | 0.120 |
Why?
|
| Caloric Restriction | 1 | 2014 | 88 | 0.120 |
Why?
|
| Perioperative Care | 2 | 2010 | 451 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 7702 | 0.120 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 254 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 2 | 2014 | 691 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 787 | 0.120 |
Why?
|
| MicroRNAs | 2 | 2018 | 2947 | 0.120 |
Why?
|
| Metastasectomy | 1 | 2016 | 200 | 0.120 |
Why?
|
| Databases, Genetic | 1 | 2017 | 745 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2022 | 1471 | 0.120 |
Why?
|
| Doxorubicin | 3 | 2020 | 3005 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 4549 | 0.120 |
Why?
|
| Transcriptome | 3 | 2019 | 1859 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 4 | 2021 | 993 | 0.110 |
Why?
|
| Risk | 5 | 2020 | 1972 | 0.110 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 622 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 311 | 0.110 |
Why?
|
| Medical Oncology | 4 | 2018 | 1423 | 0.110 |
Why?
|
| Mucormycosis | 1 | 2014 | 108 | 0.110 |
Why?
|
| Ileum | 2 | 2023 | 165 | 0.110 |
Why?
|
| Ureterostomy | 1 | 2012 | 8 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 419 | 0.110 |
Why?
|
| Sarcoma | 3 | 2020 | 1725 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2020 | 477 | 0.100 |
Why?
|
| Professional Competence | 1 | 2013 | 136 | 0.100 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2012 | 43 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2014 | 298 | 0.100 |
Why?
|
| Hemangioblastoma | 1 | 2011 | 22 | 0.100 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2016 | 690 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2011 | 74 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2012 | 2594 | 0.100 |
Why?
|
| Chyle | 1 | 2011 | 10 | 0.100 |
Why?
|
| Embolization, Therapeutic | 1 | 2016 | 551 | 0.100 |
Why?
|
| Suture Techniques | 3 | 2009 | 319 | 0.100 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 436 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 661 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2019 | 11965 | 0.100 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 255 | 0.100 |
Why?
|
| Neoplasm Transplantation | 2 | 2015 | 1519 | 0.100 |
Why?
|
| Brachytherapy | 1 | 2017 | 977 | 0.100 |
Why?
|
| Depression | 3 | 2016 | 1715 | 0.090 |
Why?
|
| Computational Biology | 1 | 2017 | 1271 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2017 | 1000 | 0.090 |
Why?
|
| Prednisone | 1 | 2013 | 984 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2014 | 584 | 0.090 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2010 | 39 | 0.090 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 11538 | 0.090 |
Why?
|
| Demography | 1 | 2011 | 435 | 0.090 |
Why?
|
| Emotions | 1 | 2014 | 562 | 0.090 |
Why?
|
| Length of Stay | 3 | 2018 | 1900 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 275 | 0.090 |
Why?
|
| Diet | 1 | 2017 | 1440 | 0.090 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2010 | 132 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
| Rectal Neoplasms | 1 | 2018 | 1202 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2010 | 355 | 0.090 |
Why?
|
| Credentialing | 1 | 2009 | 63 | 0.090 |
Why?
|
| Surgical Instruments | 1 | 2009 | 138 | 0.090 |
Why?
|
| Vincristine | 1 | 2013 | 1511 | 0.080 |
Why?
|
| Obesity | 3 | 2017 | 2884 | 0.080 |
Why?
|
| Odds Ratio | 4 | 2017 | 2316 | 0.080 |
Why?
|
| Bevacizumab | 4 | 2015 | 938 | 0.080 |
Why?
|
| Office Visits | 1 | 2009 | 97 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2045 | 0.080 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 309 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2012 | 1546 | 0.080 |
Why?
|
| Internship and Residency | 2 | 2017 | 1375 | 0.080 |
Why?
|
| Drug Administration Schedule | 3 | 2020 | 3472 | 0.080 |
Why?
|
| Reference Values | 2 | 2007 | 1099 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 2508 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2011 | 2232 | 0.080 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 604 | 0.080 |
Why?
|
| Comorbidity | 3 | 2015 | 2352 | 0.080 |
Why?
|
| Professional Practice | 1 | 2008 | 82 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1516 | 0.080 |
Why?
|
| Telomere | 2 | 2009 | 505 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2001 | 4821 | 0.080 |
Why?
|
| Ligation | 1 | 2008 | 193 | 0.080 |
Why?
|
| Fenretinide | 1 | 2008 | 96 | 0.080 |
Why?
|
| Cognition | 1 | 2014 | 968 | 0.080 |
Why?
|
| Phenotype | 2 | 2017 | 6295 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.080 |
Why?
|
| Vinblastine | 2 | 2020 | 453 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2008 | 191 | 0.070 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 195 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2014 | 1360 | 0.070 |
Why?
|
| Neoplasms | 3 | 2023 | 15193 | 0.070 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2014 | 1415 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 1375 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2001 | 5270 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2008 | 148 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2018 | 299 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 1391 | 0.070 |
Why?
|
| Societies, Medical | 3 | 2018 | 1335 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2019 | 3869 | 0.070 |
Why?
|
| Swine | 2 | 2008 | 1541 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 2488 | 0.070 |
Why?
|
| Perioperative Period | 2 | 2018 | 155 | 0.070 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2007 | 129 | 0.070 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 3001 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 543 | 0.070 |
Why?
|
| South Africa | 1 | 2005 | 92 | 0.070 |
Why?
|
| Pneumothorax, Artificial | 1 | 2005 | 4 | 0.070 |
Why?
|
| Point Mutation | 1 | 2008 | 769 | 0.070 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.070 |
Why?
|
| Thalidomide | 1 | 2008 | 569 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 2314 | 0.060 |
Why?
|
| Anastomosis, Surgical | 2 | 2023 | 371 | 0.060 |
Why?
|
| Methotrexate | 2 | 2020 | 999 | 0.060 |
Why?
|
| Androgen Antagonists | 1 | 2007 | 411 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2015 | 5178 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2173 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 585 | 0.060 |
Why?
|
| Ifosfamide | 1 | 2005 | 344 | 0.060 |
Why?
|
| Organ Sparing Treatments | 2 | 2016 | 277 | 0.060 |
Why?
|
| Postoperative Period | 2 | 2021 | 665 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2006 | 212 | 0.060 |
Why?
|
| Remission Induction | 1 | 2010 | 3569 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2007 | 627 | 0.060 |
Why?
|
| Mitomycins | 1 | 2023 | 48 | 0.060 |
Why?
|
| Holmium | 1 | 2003 | 23 | 0.060 |
Why?
|
| Oregon | 1 | 2023 | 20 | 0.060 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2003 | 14 | 0.060 |
Why?
|
| Tensile Strength | 1 | 2003 | 73 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 299 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 3 | 2015 | 5395 | 0.060 |
Why?
|
| Animals | 7 | 2017 | 59536 | 0.060 |
Why?
|
| Abdominal Muscles | 1 | 2003 | 68 | 0.060 |
Why?
|
| Germ-Line Mutation | 1 | 2008 | 1046 | 0.060 |
Why?
|
| Reoperation | 3 | 2015 | 1382 | 0.050 |
Why?
|
| Wound Healing | 2 | 2009 | 815 | 0.050 |
Why?
|
| Cost Savings | 1 | 2003 | 123 | 0.050 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 129 | 0.050 |
Why?
|
| Disease Progression | 4 | 2021 | 6682 | 0.050 |
Why?
|
| Testosterone | 1 | 2007 | 619 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2009 | 1960 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 4744 | 0.050 |
Why?
|
| Urinary Calculi | 1 | 2001 | 25 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2006 | 712 | 0.050 |
Why?
|
| Urethra | 1 | 2002 | 144 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2003 | 114 | 0.050 |
Why?
|
| Morbidity | 1 | 2003 | 397 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 6009 | 0.050 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 4298 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2021 | 1249 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 14551 | 0.050 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2001 | 5 | 0.050 |
Why?
|
| Interferon-Stimulated Gene Factor 3, gamma Subunit | 1 | 2001 | 5 | 0.050 |
Why?
|
| Inflammation | 1 | 2011 | 2522 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2005 | 588 | 0.050 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2001 | 7 | 0.050 |
Why?
|
| United States | 5 | 2020 | 15433 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 2403 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1244 | 0.050 |
Why?
|
| Genome, Human | 1 | 2009 | 1869 | 0.050 |
Why?
|
| Living Donors | 1 | 2001 | 171 | 0.050 |
Why?
|
| Interferon-beta | 1 | 2001 | 102 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 1085 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2006 | 1656 | 0.050 |
Why?
|
| Israel | 1 | 2020 | 53 | 0.050 |
Why?
|
| Genital Diseases, Female | 1 | 2001 | 60 | 0.050 |
Why?
|
| DNA Repair | 1 | 2008 | 1872 | 0.050 |
Why?
|
| Preoperative Care | 3 | 2012 | 1529 | 0.050 |
Why?
|
| Urodynamics | 1 | 2000 | 57 | 0.050 |
Why?
|
| Drug Compounding | 1 | 2020 | 70 | 0.050 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 126 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2006 | 945 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 1085 | 0.040 |
Why?
|
| Sex Factors | 2 | 2014 | 2139 | 0.040 |
Why?
|
| Genotype | 2 | 2018 | 4109 | 0.040 |
Why?
|
| Tuberous Sclerosis | 1 | 2020 | 136 | 0.040 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 2265 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2018 | 2218 | 0.040 |
Why?
|
| Peritoneal Dialysis | 1 | 2000 | 125 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 5437 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 332 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 3719 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2018 | 257 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2015 | 4307 | 0.040 |
Why?
|
| Microsurgery | 2 | 2004 | 244 | 0.040 |
Why?
|
| Neuropeptide Y | 1 | 2017 | 47 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 684 | 0.040 |
Why?
|
| Dietary Fiber | 1 | 2017 | 123 | 0.040 |
Why?
|
| Mice | 3 | 2017 | 34495 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2005 | 1303 | 0.040 |
Why?
|
| Stents | 1 | 2003 | 1096 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2001 | 1070 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2001 | 1144 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 700 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2009 | 497 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 1033 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2018 | 374 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 233 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2017 | 369 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 85 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 649 | 0.030 |
Why?
|
| Transfection | 1 | 2001 | 2944 | 0.030 |
Why?
|
| Leptin | 1 | 2017 | 295 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2010 | 669 | 0.030 |
Why?
|
| Child | 3 | 2016 | 29154 | 0.030 |
Why?
|
| Clinical Studies as Topic | 1 | 2014 | 19 | 0.030 |
Why?
|
| Quinoxalines | 1 | 2015 | 95 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 583 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2015 | 166 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 178 | 0.030 |
Why?
|
| Keratin-7 | 1 | 2014 | 52 | 0.030 |
Why?
|
| Fellowships and Scholarships | 2 | 2009 | 390 | 0.030 |
Why?
|
| Neprilysin | 1 | 2014 | 66 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2017 | 556 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 750 | 0.030 |
Why?
|
| Hyphae | 1 | 2014 | 44 | 0.030 |
Why?
|
| Urologic Diseases | 1 | 2014 | 78 | 0.030 |
Why?
|
| Monosomy | 1 | 2014 | 95 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 1586 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2008 | 672 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2017 | 741 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 1048 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2019 | 2074 | 0.030 |
Why?
|
| Prevalence | 2 | 2015 | 3260 | 0.030 |
Why?
|
| Calcium | 1 | 2000 | 1537 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2017 | 7226 | 0.030 |
Why?
|
| Hydronephrosis | 1 | 2013 | 50 | 0.030 |
Why?
|
| Computer Systems | 1 | 2013 | 106 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2015 | 403 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 68 | 0.030 |
Why?
|
| Social Support | 1 | 2016 | 560 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2015 | 538 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 760 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 733 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 422 | 0.030 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2012 | 7 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 1544 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2015 | 582 | 0.030 |
Why?
|
| China | 1 | 2013 | 606 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2011 | 67 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2011 | 70 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2008 | 16273 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 1454 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2017 | 808 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 2084 | 0.030 |
Why?
|
| Health Policy | 1 | 2014 | 291 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 1439 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 328 | 0.020 |
Why?
|
| NADPH Oxidases | 1 | 2011 | 146 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2011 | 113 | 0.020 |
Why?
|
| Urine | 1 | 2011 | 143 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 673 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2001 | 6150 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 1054 | 0.020 |
Why?
|
| Urinalysis | 1 | 2011 | 84 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2017 | 1682 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.020 |
Why?
|
| Sleep Wake Disorders | 1 | 2014 | 348 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2016 | 2588 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 992 | 0.020 |
Why?
|
| Imidazoles | 1 | 2015 | 999 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 3101 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2010 | 140 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 2009 | 960 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 2014 | 1914 | 0.020 |
Why?
|
| Adrenergic Antagonists | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 5637 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 690 | 0.020 |
Why?
|
| Contracts | 1 | 2008 | 11 | 0.020 |
Why?
|
| Time Management | 1 | 2008 | 16 | 0.020 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2008 | 106 | 0.020 |
Why?
|
| Private Practice | 1 | 2008 | 31 | 0.020 |
Why?
|
| Contrast Media | 1 | 2015 | 1472 | 0.020 |
Why?
|
| Negotiating | 1 | 2008 | 17 | 0.020 |
Why?
|
| B7-H1 Antigen | 1 | 2015 | 1022 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 383 | 0.020 |
Why?
|
| Job Application | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Laser Scanning Cytometry | 1 | 2007 | 16 | 0.020 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2009 | 388 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 1217 | 0.020 |
Why?
|
| Mitochondria | 1 | 2014 | 1282 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 945 | 0.020 |
Why?
|
| Fatigue | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2008 | 178 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 437 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3821 | 0.020 |
Why?
|
| Specialization | 1 | 2008 | 130 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2007 | 316 | 0.020 |
Why?
|
| Mass Screening | 1 | 2015 | 1509 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 2307 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 1265 | 0.020 |
Why?
|
| Electrodes | 1 | 2005 | 116 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1819 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Exons | 1 | 2008 | 1328 | 0.020 |
Why?
|
| Quinazolines | 1 | 2009 | 923 | 0.020 |
Why?
|
| Pedigree | 1 | 2008 | 1890 | 0.020 |
Why?
|
| Kinetics | 1 | 2007 | 2049 | 0.020 |
Why?
|
| Adenoma | 1 | 2009 | 716 | 0.010 |
Why?
|
| Kidney Calices | 1 | 2003 | 7 | 0.010 |
Why?
|
| Apoptosis | 1 | 2017 | 7591 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3552 | 0.010 |
Why?
|
| Tissue Expansion | 1 | 2003 | 71 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 4917 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 4557 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 4849 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 1618 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 6089 | 0.010 |
Why?
|
| Biomarkers | 1 | 2012 | 5047 | 0.010 |
Why?
|
| Equipment Design | 1 | 2004 | 1204 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 3343 | 0.010 |
Why?
|
| Cell Line | 1 | 2007 | 5114 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 4320 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2001 | 755 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2008 | 3341 | 0.010 |
Why?
|